+Compare
SONN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
2.61M

SONN Sonnet BioTherapeutics Holdings Forecast, Technical & Fundamental Analysis

a company, which engages in the development of biologic drugs with enhanced single or bispecific mechanisms

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for SONN with price predictions
07:00 PM EST Dec 07, 2023

SONN saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for SONN moved out of overbought territory on November 30, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 34 similar instances where the indicator exited the overbought zone. In of the 34 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SONN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SONN broke above its upper Bollinger Band on December 04, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SONN's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 22, 2023. You may want to consider a long position or call options on SONN as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SONN just turned positive on November 02, 2023. Looking at past instances where SONN's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SONN advanced for three days, in of 197 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 84 cases where SONN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.743) is normal, around the industry mean (20.733). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (5.435) is also within normal values, averaging (330.425).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SONN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SONN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 10,162%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was 27%. OZYMD experienced the highest price growth at 8,999,901%, while ZVSA experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -10%. For the same stocks of the Industry, the average monthly volume growth was 4% and the average quarterly volume growth was 51%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 28 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

SONN is expected to report earnings to rise 3,061.54% to -411 cents per share on November 29

Sonnet BioTherapeutics Holdings SONN Stock Earnings Reports
Q3'23
Est.
$-4.11
Q2'23
Beat
by $0.16
Q1'23
Beat
by $0.05
Q4'22
Beat
by $0.33
Q3'22
Est.
$-1.51
The last earnings report on August 14 showed earnings per share of -12 cents, beating the estimate of -28 cents. With 122.86K shares outstanding, the current market capitalization sits at 2.61M.
A.I. Advisor
published General Information

General Information

a company, which engages in the development of biologic drugs with enhanced single or bispecific mechanisms

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Overlook Center
Phone
+1 609 375-2227
Employees
12
Web
https://www.sonnetbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALLR0.560.07
+15.00%
Allarity Therapeutics
EDN17.600.71
+4.20%
Empresa Distribuidora Y Comercializadora Norte SA
IFRX1.440.04
+2.86%
InflaRx NV
WCC160.963.26
+2.07%
Wesco International
HCAT7.760.06
+0.78%
Health Catalyst

SONN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SONN has been loosely correlated with UBX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if SONN jumps, then UBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
-0.64%
UBX - SONN
33%
Loosely correlated
-0.53%
VIRI - SONN
27%
Poorly correlated
+6.08%
AVRO - SONN
26%
Poorly correlated
+1.44%
PHAR - SONN
25%
Poorly correlated
N/A
NCNA - SONN
25%
Poorly correlated
-2.38%
More